

Journal section: Oral Medicine and Pathology

Publication Types: Research

doi:10.4317/jced.59769

https://doi.org/10.4317/jced.59769

## Aberrant immunoeexpression of p53 tumour-suppressor and Bcl-2 family proteins (Bcl-2 and Bax) in ameloblastomas and odontogenic keratocysts

Enrico Escobar <sup>1</sup>, Fernán Gómez-Valenzuela <sup>2</sup>, Cristian Peñafiel <sup>1</sup>, Eduardo Chimenos-Küstner <sup>3</sup>, Ricardo Pérez-Tomás <sup>4</sup>

<sup>1</sup> Department of Oral Pathology and Medicine, Faculty of Dentistry, University of Chile, Santiago, Chile

<sup>2</sup> Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

<sup>3</sup> Department of Odonto-Stomatology, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain

<sup>4</sup> Department of Pathology and Experimental Therapy -Bellvitge, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain

### Correspondence:

Centro de Investigaciones Médicas (CIM)

Marcoleta 391, Santiago, Región Metropolitana

Zip code: #8330024

fdgomez2@uc.cl

Escobar E, Gómez-Valenzuela F, Peñafiel C, Chimenos-Küstner E, Pérez-Tomás R. Aberrant immunoeexpression of p53 tumour-suppressor and Bcl-2 family proteins (Bcl-2 and Bax) in ameloblastomas and odontogenic keratocysts. J Clin Exp Dent. 2023;15(2):e125-34.

Received: 01/06/2022

Accepted: 07/12/2022

Article Number: 59769 <http://www.medicinaoral.com/odo/indice.htm>

© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488

eMail: jced@jced.es

### Indexed in:

Pubmed  
 Pubmed Central® (PMC)  
 Scopus  
 DOI® System

### Abstract

**Background:** The growth of ameloblastomas (odontogenic tumours) and odontogenic keratocyst (OKC) (developmental cyst) is associated with the expression of proteins related to cell survival and apoptosis. Bcl-2-associated protein X (Bax) and the tumour suppressor protein p53 collectively promote p53-mediated apoptosis. This study aimed to assess the immunohistochemical expression of p53, Bcl-2 and Bax in conventional ameloblastoma (CA), unicystic ameloblastoma (UA) types, and OKC sporadic (OKC-NS/S) and syndromic (OKC-NBSCC).

**Material and Methods:** Paraffinized blocks of CA (n=18), UA (n=15), OKC-NS/S (n=18) and OKC-NBSCC (n=15) fixed in 10% formalin were used. After diagnosis, tissue specimens were stained by immunohistochemistry for p53, Bcl-2 and Bax marker. Stained cells were randomly counted in five high power fields. The data analysis was performed via Shapiro-Wilk test, ANOVA with Tukey's multiple comparisons or Kruskal-Wallis with Dunn's multiple comparisons. Statistical significance was defined as  $p < 0.05$ .

**Results:** We did not observe differences between p53 expression in CA, mural UA (MUA), intraluminal/luminal UA (I/LUA), OKC-NS/S, and OKC-NBSCC (19.69%, 18.74%, 16.76%, 12.35% and 9.04%, respectively). Similar results were recognized for Bax expression in CA, MUA, I/LUA, OKC-NS/S, and OKC-NBSCC (33.72%, 34.95%, 22.94, 21.58% and 20.76%, respectively). However, we recognized significant differences between Bcl-2 expression in OKC-NS/S vs MUA, OKC-NS/S vs I/LUA, OKC-NS/S vs CA, OKC-NBSCC vs MUA, OKC-NBSCC vs I/LUA, and I/LUA vs CA. P53, Bcl-2 and Bax levels were higher in mural morphological areas versus intraluminal and luminal morphological areas in UA.

**Conclusions:** There is a tendency for an increased expression of p53, Bcl-2, and Bax proteins in CA, and mural proliferation of UA, compared to lesions with a cystic morphology, which could be associated with a local aggressive behaviour.

**Key words:** p53, Bcl-2, Bax protein, apoptosis, odontogenic tumour, odontogenic cyst.

## Introduction

Apoptosis represents a form of programmed cell death that plays a role in the homeostasis of tissues (1). However, alterations in various cell signalling pathways can lead to dysregulation of apoptosis and promote tumorigenesis (1).

There are two main apoptotic pathways: the extrinsic and the intrinsic or mitochondrial pathway (1). P53, Bcl-2 and Bax proteins are among the most studied effectors during the intrinsic pathway of apoptosis. P53 is a primary orchestrator of the cellular response to a broad array of stress types by regulating apoptosis, cell cycle arrest, senescence, DNA repair and genetic stability (2). P53 participates directly in the intrinsic apoptosis pathway by interacting with the multidomain members of the Bcl-2 family. The Bcl-2 family determines the commitment of cells to apoptosis (2,3). The Bcl-2 protein is an anti-apoptotic molecule that modulates the mitochondrial release of cytochrome c, and the interaction of apoptosis activating factors with caspase 9 and Bax. P53-dependent signals, including the induction of Bax and direct inhibition of Bcl-2, synergize with p53-independent signals to antagonize Bcl-2 function and promote apoptosis (3). Bax, a pro-apoptotic member of Bcl-2 family, has been considered as a potential tumour suppressor (2,3). P53 regulates the transcription of Bax gene and the loss of p53 function causes diminished expression of Bax protein (4).

Conventional ameloblastoma (CA), unicystic ameloblastoma (UA) and odontogenic keratocyst (OKC) are common lesions in the jaws. CA is the most frequent of the benign epithelial odontogenic tumours (5). UA represents a distinct type of ameloblastoma regarded as a neoplastic cyst (5). Likewise, UA is typified according to cellular growth as luminal UA (LUA), intraluminal UA (IUA), and mural UA (MUA). In LUA and IUA, the cystic wall is not invaded by growth of the luminal lining (5). In contrast, MUA presents a compromise of the cystic wall with involvement towards a locally aggressive behaviour (5).

The current 2022 World Health Organization (WHO) odontogenic tumours classification identifies OKC as a nonneoplastic cyst with the potential for aggressive behaviour and a tendency for local recurrence (6). Moreover, OKC development is related to naevoid basal cell carcinoma syndrome (NBCCS) (6). The biologic behaviour of syndromic OKC (OKC-NBCCS) has been described as more aggressive and with higher recurrence rates compared with OKC non-syndromic or sporadic OKC (OKC-NS/S) (7).

The expression of p53, Bcl-2 and Bax proteins has been studied in various pathological lesions, especially malignant neoplasms (8). Nevertheless, research about the expression of p53, Bcl-2 and Bax proteins in odontogenic lesions is scarce, particularly for samples from

Latin-America. Interestingly, the expression of proteins related to tumour-suppression genes (p53), and Bcl-2 family could be independent of the morphological characteristics of solid and cystic odontogenic lesions.

In this fashion, this study aimed to analyse and compare the expression of p53, Bcl-2 and Bax proteins in CA, UA, OKC-NS/S, and OKC-NBCCS as odontogenic lesions with a similar clinical-biological behaviour, but morphologically different, by immunohistochemical study.

## Material and Methods

**Sample selection.** A sample of 66 cases was collected. All cases and demographic data were retrieved from the Pathological Anatomy Service, University of Chile, from 1997 to 2016. Haematoxylin-eosin-stained slides were studied by two pathologists and re-evaluated and diagnosed according to 5th edition of the WHO (2022). Previously, a Cohen's Kappa ( $\kappa$ ) coefficient was performed by two calibrated observers ( $\kappa$ -value= 0.81±0.12 with a 95% confidence interval of 0.56 to 1.00) for the histological diagnosis of CA, UA and OKC. The cases were distributed into four categories: CA (n=18), UA (n=15) according to histologic types: luminal and/or intraluminal UA (I/LUA) (n=7), and luminal and mural and/or intraluminal UA (MUA) (n=8), and OKC (n=33) according to OKC-NS/S (n=18) and OKC-NBCCS (n=15). Two subcategories for UA were considered according to their dissimilar clinicopathological behaviour and treatment, especially for UA with mural proliferation. The diagnosis for NBCCS was made according to Bree and Shah's criteria (9). Lesions with an inflammatory infiltrate (moderate to intense) were excluded following the criteria of Clark *et al.* (10). Likewise, recurrent lesions or lesions obtained after decompression therapy were excluded.

**Immunostaining method.** Four- $\mu$ m thick sections from paraffin-embedded blocks in a Reichert-Jung® Biocut Microtom (Mod.1130/Biocut) were placed on positively charged slides (CellPath Ltd.). Cases were deparaffinized in xylene for 20 minutes (min) and hydrated in graded ethanol. Next, the slides were placed on distilled water for 10 min. Deparaffinized slides were placed in PBS (pH=7.4±0.2). Subsequently, the slides were immersed in 10mM citrate buffer solution (pH=6.0) for antigen retrieval and were transferred to Oster® Food Steamer until the boiling point. The cases were maintained for 20 min and left for cooling until 21°C. Internal peroxidase activity was blocked using 3% hydrogen peroxide and Mouse/Rabbit Immunodetector Peroxidase Blocker Solution (BSB0003, Bio SB) for 20 min each at room temperature. Primary monoclonal antibodies (Table 1) from Bio SB Inc. were incubated overnight at 4°C for mouse anti-human P53 (BSB5842, clone: DO7, Ready-To-Use); mouse anti-human Bcl-2 (BSB5075,

Table 1: Details of primary antibodies employed.


Primary Antibody	Supplier	Catalog Number	Type of Antibody	Clone	Isotype	Localization	Dilution	Species Reactivity	Reactivity	Incubation	External positive control
P53	Bio SB, Santa Barbara, CA, U.S.A.	BSB 5842	Mouse Monoclonal	DO7	Ig-G2b/K	Nuclear	Ready-To-Use	Human	Paraffin	Overnight 4°C	Oral Squamous Cell Carcinoma
Bcl-2	Bio SB, Santa Barbara, CA, U.S.A.	BSB 5075	Mouse Monoclonal	BCL2/A4	IgG1/K	Cytoplasmic	Concentrated	Human	Paraffin	Overnight 4°C	Non-Hodgkin lymphoma
Bax	Bio SB, Santa Barbara, CA, U.S.A.	BSB 6079	Rabbit Monoclonal	E63	IgG	Cytoplasmic, Cell Membranous	Ready-To-Use	Human	Paraffin	Overnight 4°C	Amygdala

clone: BCL2/A4, Concentrated), and rabbit anti-human Bax (BSB6079, clone: E63, Ready-To-Use).


Next, the cases were incubated with Mouse Immuno-Detector Biotin-Link and mouse/rabbit Immuno-Detector HRP Label (BSB0003) for 20 min each at room temperature. PBS was used as a wash buffer for 30 min when required between each stage. Peroxidase reaction was performed with chromogen 3,3'-diaminobenzidine reagent. The cases were slightly counterstained with Harris's haematoxylin solution for one minute. Oral squamous cell carcinoma (Fig. 1G), non-Hodgkin lymphoma (Fig. 2G) and amygdala (Fig. 3G) were used as a positive external control for p53, Bcl-2 and Bax proteins, respectively. Immunostaining of stromal lymphocytes was utilized as internal positive control for Bcl-2 and Bax proteins. Negative external controls (Figs. 1H,2H) (Fig. 3H) were the same samples of external positive controls incubated with phosphate-buffered saline (PBS; PBS-9990, BION) instead of primary antibodies.

Immunohistochemical scoring. Odontogenic epithelial cell (OEC) immunostaining was quantitatively assessed by estimating the percentage of stained cells per high-power field (HPF) with magnification of 400x. In UA, quantification of p53; Bcl-2 and Bax immunostaining considered to I/LUA: lining epithelium and intraluminal proliferation, and for MUA: exclusively proliferation mural. Moreover, areas characterized morphologically as luminal, intraluminal, and mural were quantified in each case of UA. Five photomicrographs were captured with a digital camera in an optical microscope (Olympus BX41, Tokyo, Japan) for each case in areas with abundant OEC by HPF. Microphotographs were taken and processed with the LEICA application suite software program (v4.7.1). All images were stored in TIF format. Cells were counted by two independent observers using the ImageJ free software. P53 immunoeexpression was assessed for the nuclear staining, instead, Bcl-2 and Bax protein immunoeexpression was assessed for the cytoplasmic staining. Stained and total number of OEC were counted in five HPF. The number of positive cells for immunoreactivity was counted and calculated as a percentage relative to the total cells. Previously, we performed the Bland–Altman test (a bias of 4.86±4.61 with a 95% confidence interval from -4.17 to 13.88) to analyse the interobserver agreement of the immunoeexpression count.

Statistical analysis. Statistical analysis was performed using R Statistical Software (v4.1.2; R Foundation for Statistical Computing, Vienna, Austria). First, we conducted a heteroskedasticity examination. Next, we analysed the data distribution using the Shapiro-Wilk test. Consequently, we performed statistics using one-way ANOVA with Tukey's multiple comparison test or Kruskal-Wallis with Dunn's multiple comparisons with Holm's correction. Last, we conducted Spearman corre-



**Fig. 1:** Immunohistochemical protein expression of p53 (400x). (A) conventional ameloblastoma; (B) luminal unicystic UA; (C) intraluminal UA; (D) mural UA; (E), OKC non-syndromic or sporadic; (F), OKC related NBSCC; (G), EPC: oral squamous cell carcinoma; (H), ENC: oral squamous cell carcinoma. Abbreviations: UA: unicystic ameloblastoma; EPC: external positive control; ENC: external negative control; OKC: odontogenic keratocyst; NBSCC: naevoid basal cell carcinoma syndrome.




**Fig. 2:** Immunohistochemical protein expression of Bcl-2 (400x). (A) conventional ameloblastoma; (B) luminal unicystic UA; (C) intraluminal UA; (D) mural UA; (E), OKC non-syndromic or sporadic; (F), OKC related NBSCC; (G), EPC: non-Hodgkin lymphoma; (H), ENC: non-Hodgkin lymphoma. Abbreviations: UA: unicystic ameloblastoma; EPC: external positive control; ENC: external negative control; OKC: odontogenic keratocyst; NBSCC: naevoid basal cell carcinoma syndrome.

lation analysis to observe potential correlations. Statistical significance was defined as  $p < 0.05$ .

## Results

Clinical-demographic characteristics. The clinical-demographic features are summarized in Table 2.

Males and females had a similar prevalence. The mean age of prevalence of all studied lesions was 31.61 years with a median of 22.50 years. OKC-NBCSS was the earliest average diagnosis (16.47 years). The location in the mandible ( $n=56$ ) was significantly greater than those observed in the maxilla ( $n=10$ ), particularly in posterior



**Fig. 3:** Immunohistochemical protein expression of Bax (400x). (A) conventional ameloblastoma; (B) luminal unicystic UA; (C) intraluminal UA; (D) mural UA; (E), OKC non-syndromic or sporadic; (F), OKC related NBSCC; (G), EPC: amygdala; (H), ENC: amygdala. Abbreviations: UA: unicystic ameloblastoma; EPC: external positive control; ENC: external negative control; OKC: odontogenic keratocyst; NBSCC: naevoid basal cell carcinoma syndrome.

areas of CA and UA. Overall, SA was the most symptoms-related lesion.

**P53 protein expression.** We observed a higher p53 expression in CA, MUA, and I/LUA than OKC-NS/S and OKC-NBSCC; however, no statistical differences were found between these groups (Table 3, A). Likewise, no statistical differences were observed among luminal, intraluminal, and mural areas of UA for p53 expression. In CA, peripheral ameloblast-like cells and stellate reticulum-like cells showed positive brown nuclear p53 immunostaining (Fig. 1A). In UA, positive brown nuclear p53 immunostaining was detected in basal (ameloblast-like) and suprabasal (stellate reticulum-like) layers (Fig. 1B-D). In intraluminal and mural areas of UA, positive nuclear p53 immunostaining was observed both in peripheral ameloblast-like cells and stellate reticulum-like cells (Fig. 1B-D). In OKC-NS/S and OKC-NBSCC, positive brown nuclear p53 immunostaining was detected both in basal and suprabasal compartments of the epithelial lining (Fig. 1E-F).

**Bcl-2 protein expression.** Statistical differences were recognized between OKC-NS/S vs MUA, OKC-NS/S vs I/LUA, OKC-NS/S vs CA, OKC-NBSCC vs MUA, OKC-NBSCC vs I/LUA, and I/LUA vs CA. Bcl-2 immunostaining in CA was cytoplasmic and mainly located in peripheral ameloblast-like cells (Fig. 2A). In UA, predominant staining was also observed in ameloblast-like cells (Fig. 2B-D). In OKC-NS/S and OKC-NBSCC, immunostaining was cytoplasmic and localized to the basal cells of the epithelial lining and sometimes

to the parabasal cells. The cells of the suprabasal compartments were negative for the immunoeexpression of the Bcl-2 protein (Fig. 2E-F).

**Bax protein expression.** We observed a higher Bax expression in CA and MUA than OKC-NS/S and OKC-NBSCC; however, no statistical differences were found between these groups (Table 3A). Likewise, no statistical difference was found among luminal, intraluminal, and mural areas of UA for Bax expression. Bax immunostaining in CA was cytoplasmic and located in peripheral ameloblast-like cells and stellate reticulum-like cells (Fig. 3A). In UA, positive brown cytoplasmic Bax immunostaining was detected mainly in basal (ameloblast-like) and suprabasal layers (stellate reticulum-like) (Fig. 3B-D). In intraluminal and mural areas of UA, positive cytoplasmic Bax immunostaining was observed both in peripheral ameloblast-like cells and stellate reticulum-like cells (Fig. 3B-D). In OKC-NS/S and OKC-NBSCC, a positive brown cytoplasmic Bax immunostaining was observed both in basal and suprabasal epithelial compartment (Fig. 3E-F).

**Protein immunoeexpression comparison.** The summary of the mean of P53, Bcl-2 and Bax immunoeexpression and its comparison between OKC-NS/S, OKC-NBSCC, CA, MUA and I/LUA are presented in Table 3, A and between morphological areas of UA are presented in Table 4, A. Spearman's test showed a non-statistical correlation between p53 and Bax in the lesions analysed (rho-values for: MUA= 0.37; I/LUA= -0.26; OKC-NS/S= 0.17; OKC-NBSCC= 0.001; and CA=0.25).

**Table 2:** Clinical-demographic characteristics of the involved patients and distribution of the lesions by anatomic location.

Variable	Total	CA	UA		OKC-NS/S	OKC-NBCCS
			I/LUA†	MUA		
Cases (n)	66	18	7	8	18	15
Age (years)						
Range	8-75	16-75	17-49	8-68	9-67	9-47
Mean	31.61	44.61	24.70	39.50	30.50	16.47
± SD	19.39	19.01	11.57	22.21	17.80	8.94
Median	22.50	44.50	22	44.50	22.50	15
Sex: n (%) *						
Male	27 (42.19)	8 (44.44)	2 (28.57)	6 (75.00)	7 (38.89)	5 (33.33)
Female	37 (57.81)	10 (55.56)	5 (71.42)	2 (25.00)	11 (61.11)	10 (66.67)
Anatomic Location: n (%) *						
Maxilla	10	5	0	0	0	3
Anterior	3 (30.00)	1 (20.00)	0	0	0	1(33.33)
Posterior	7 (70.00)	4 (80.00)	0	0	0	2 (66.67)
Mandible	56	13	7	8	18	12
Anterior	8 (14.29)	1 (7.69)	1 (14.28)	1 (12.50)	4 (22.22)	2 (16.67)
Posterior	48 (85.71)	12 (92.31)	6 (85.71)	7 (87.50)	14 (77.78)	10 (83.33)
Swelling or expansion of the jaws: n (%) *						
Cases	39 (59.09)	15 (83.33)	0	6 (75.00)	10 (55.56)	8 (47.06)
Cortical perforation: n (%) *						
Cases	13 (19.70)	5 (27.78)	2 (28.57)	2 (25.00)	3 (16.67)	3 (17.65)
Symptomatology (pain): n (%) *						
Cases	26 (39.39)	9 (50.00)	2 (28.57)	3 (37.50)	10 (55.56)	4 (23.53)
Relationship with teeth: mobility n (%) *						
Cases	5 (7.57)	0 (27.78)	0	2 (25.00)	2 (11.11)	1 (6.66)
Relationship with included tooth; n (%) *						
Cases	23 (34.84)	5 (27.77)	4 (57.14)	2 (25.00)	6 (33.33)	6 (40.00)

† Two exclusive luminal UA type

\* Calculated as a percentage for each lesion

CA, conventional ameloblastoma; UA, unicystic ameloblastoma; I/LUA, intraluminal and/or luminal unicystic ameloblastoma; MUA, mural unicystic ameloblastoma; OKC-NS/S, non-syndromic or sporadic OKC; OKC-NBCCS, OKC associated with nevoid basal cell carcinoma syndrome (NBCCS); SD, standard deviation.

Comparison of Bcl-2/Bax ratio. We observed that the Bcl-2/Bax ratio classified according to higher Bcl-2 expression (ratio >1) or higher Bax expression (ratio <1) was similar between OKC-NS/S, OKC-NBCCS, CA, MUA, and I/LUA (Table 3B). However, we observed a trend of Bcl-2/Bax ratio >1 in all morphological areas of UA (Table 4B).

**Discussion**

The evasion of apoptosis induces tumourigenesis and tumour progression. The p53 gene is frequently mutated in various human tumours (11). P53 interacts with Bcl-2 and neutralizes their inhibitory effects on Bax, as well as p53 stimulates the expression of proapoptotic Bcl-2

family, including Bax (12). Indeed, Bax is a downstream effector of p53-induced apoptosis and is transcriptionally regulated by p53 (11). The positive correlation between the p53 activity (wild type p53) and Bax (4) is based on various p53-responsive elements in the Bax gene promoter (13).

The immunodetection of the p53 protein presents the following considerations: wild-type-p53 protein has a very short half-life in normal cells and is practically undetectable by immunohistochemical staining (13). However, p53 inactivated through mutations, deletions or binding to other proteins results in a P53 protein accumulation that immunohistochemistry can detect (14).

Increased expression of p53 protein has been related to

**Table 3.** A. Mean  $\pm$  SD and comparison of p53 and Bax protein expression (%) for OKC-NS/S (n=18), OKC-NBCCS (n=15), MUA (n=8), I/LUA (n=7) and CA (n=18).  
 Significant difference among means ( $P < 0.05$ )? (Lesion vs.) for (A) P53, (B) Bcl-2 and (C)

Lesion	Protein ( $\pm$ SD)			Bax				
	(A) P53	(B) Bcl-2	(C) Bax	OKC-NBCCS vs OKC-NS/S	MUA vs OKC-NS/S	I/LUA vs OKC-NS/S	CA vs OKC-NS/S	
OKC-NS/S	12.35 ( $\pm$ 9.27)	30.08 ( $\pm$ 11.82)	21.58 ( $\pm$ 17.88)	(A) No, $p=0.99$ (B) No, $p=0.27$ (C) No, $p=0.99$	(A) No, $p=0.49$ (B) Yes, $p=0.0098$ (C) No, $p=0.20$	(A) No, $p=0.53$ (B) Yes, $p=0.0047$ (C) No, $p=0.99$	(A) No, $p=0.99$ (B) Yes, $p=0.0085$ (C) No, $p=0.10$	
OKC-NBCCS	9.04 ( $\pm$ 8.37)	33.92 ( $\pm$ 7.81)	20.76 ( $\pm$ 14.10)	MUA vs OKC-NBCCS (A) No, $p=0.45$ (B) Yes, $p=0.0199$ (C) No, $p=0.18$	I/LUA vs OKC-NBCCS (A) No, $p=0.31$ (B) Yes, $p=0.0136$ (C) No, $p=0.99$	CA vs OKC-NBCCS (A) No, $p=0.18$ (B) Yes, $p=0.0219$ (C) No, $p=0.09$		
MUA	18.64 ( $\pm$ 11.06)	57.85 ( $\pm$ 22.56)	34.95 ( $\pm$ 10.15)	I/LUA vs MUA (A) No, $p=0.99$ (B) No, $p=0.5142$ (C) No, $p=0.50$	CA vs MUA (A) No, $p=0.99$ (B) No, $p=0.7035$ (C) No, $p=0.99$			
I/LUA	16.76 ( $\pm$ 6.24)	51.46 ( $\pm$ 13.67)	22.94 ( $\pm$ 5.97)	CA vs I/LUA (A) No, $p=0.99$ (B) No, $p=0.8194$ (C) No, $p=0.46$				
CA	19.69 ( $\pm$ 15.20)	53.59 ( $\pm$ 32.36)	33.72 ( $\pm$ 14.70)					
<b>B. Bcl-2/Bax ratio (count) for OKC-NS/S, OKC-NBCCS, MUA, I/LUA and CA.</b>								
	Bcl-2/Bax ratio >1			Bcl-2/Bax ratio <1				Total
OKC-NS/S	6			12				18
OKC-NBCCS	3			12				15
MUA	1			7				8
I/LUA	0			7				7
CA	5			13				18

**Table 4:** A. Mean ± SD and comparison of expression (%) for morphological areas of Unicystic Ameloblastoma (UA): mural (n=8), intraluminal (n=9) and luminal (n=15).

A. Mean ± SD and comparison of expression (%) for morphological areas of Unicystic Ameloblastoma (UA): mural (n=8), intraluminal (n=9) and luminal (n=15).				
Protein	UA morphological areas	Mean	±SD	Significant difference among means (p<0.05)? (vs)
p53	Mural	18.64	11.06	Mural - Intraluminal (No, p=0.944) Mural - Luminal (No, p=0.984) Luminal - Intraluminal (No, p=0.979)
	Intraluminal	15.52	5.02	
	Luminal	16.12	8.64	
Bcl-2	Mural	57.85	22.56	Mural - Intraluminal (No, p=0.944) Mural - Luminal (Yes, p=0.044) Luminal - Intraluminal (No, p=0.984)
	Intraluminal	53.83	14.47	
	Luminal	40.19	12.45	
Bax	Mural	34.95	10.15	Mural - Intraluminal (No, p=0.453) Mural - Luminal (No, p=0.087) Luminal- Intraluminal (No, p=0.653)
	Intraluminal	29.39	9.21	
	Luminal	25.87	9.12	
B. Bcl-2/Bax ratio (count) for morphological areas of UA.				
	Bcl-2/Bax ratio >1	Bcl-2/Bax ratio <1	Total	
Mural	7	1	8	
Intraluminal	8	1	9	
Luminal	13	2	15	
ANOVA one-way with Tukey's multiple comparisons test. SD, standard deviation				

increased proliferative potential, which is involved in tumoural development and progression in OKC, UA and SA (15). In our study, the means of p53 protein immunoeexpression were higher in SA and MUA versus OKC NS/S and OKC-NBSCC. However, no statistically significant differences were observed, agreeing with other studies that compared the immunoeexpression of p53 in SA, UA, and OKC (16), and SA and OKC (17,18). Interestingly, other studies reported higher levels of p53 in OKC, followed by SA and UA (15), suggesting that the elevated p53 expression in OKC and SA reveals similarity in their locally aggressive biological behaviour (15,16).

Several studies have analysed the expression of p53 protein in UA (15,16), however, analysis by type/variety of UA has been described in only a few of these studies (19). The evaluation of the molecular expression by type/variety of UA should be carefully considered because of the differential clinical-pathological behaviour and treatment, particularly with lesions exhibiting mural growth.

Indeed, we found the highest levels of p53 in SA, MUA, and I/LUA. Other studies have reported elevated levels of p53 protein in UA compared to SA, especially for histological types of UA with mural proliferation (19). These data suggest that the centrifugal growth patterns from the luminal epithelium would be related to abnormal levels of p53 in UA.

A distinctive molecular expression pattern has been described for syndromic and non-syndromic OKC (7). The overexpression of p53 protein has been described with

statistical significance in OKC-NBSCC compared to OKC-NS/S (20). Nevertheless, in our study no significant difference was observed between OKC-NBSCC and OKC-NS/S. Similar results are observed in other studies (21). Notably, immunolocalization parameters of p53 protein were observed at basal and suprabasal compartments of the epithelial lining of OKC. Immunodetection in the suprabasal compartment would be related to a longer G1 phase (21). Therefore, the biological behaviour of OKC may be related to the suprabasal proliferative compartment in the cystic epithelium. These dates suggested that a higher rate of epithelial lining proliferation is associated with p53 overexpression (22). Overall, the increase of inactivated p53 in odontogenic tumours and cysts induces impairment of the control of cell cycle, leading to an intrinsic growth potential that would be related to the potential locally aggressive behaviour (15,22).

In our study, immunoeexpression of Bcl-2 protein was observed mainly in the basal compartment of the epithelial lining for OKC-NS/S and OKC-NBSCC and in ameloblast-like cells for CA and UA. Higher levels of the anti-apoptotic protein Bcl-2 suggest that inhibition of apoptosis could promote increased cell proliferation in these epithelial cell populations. Likewise, greater immunoeexpression of Bcl-2 protein were detected in CA and UA compared to OKC-NS/S and OKC-NBSCC. In other studies, ameloblastoma showed stronger Bcl-2 protein expression than OKC (23), and higher expression of Bcl-2 protein in CA compared to UA (24), while, in a study for OKC-NS/S and OKC-NBSCC, Bcl-2 did not show significant difference (20).



Although investigations about the expression of the p53 and Bcl-2 detected by immunohistochemistry in tumours and cyst odontogenic are extensive (15-17,19-21,22), studies about Bax protein expression in odontogenic lesions are scarce (17,23-25). Similar to our study, González-González *et al.* (24) detected higher expression of Bax protein in MUA compared to LUA and IUA. We suggest that lower expression of the pro-apoptotic Bax protein in the luminal epithelial lining of UA could be related to tumour proliferative potential and cell growth towards the cystic cavity and the cystic wall.

Various studies described the expression of Bax protein in OKC (17,23,25), but they exclude the cases associated with NBSCC. In our study, the expression of Bax in OKC-NBSCC was lower than in OKC-NS/S. Eventually, the context of p53 overexpression and reduced expression of proapoptotic factors (Bax) would participate in the tumour development of OKC. However, some studies suggest that the exclusive analysis of Bax protein expression does not reflect the biological behaviour for OKC (25). Indeed, tumour cells can acquire resistance to apoptosis by subexpression and/or mutation of Bax or by the overexpression of Bcl-2, both proteins regulated by p53 gene (4).

P53 participates directly in the intrinsic apoptosis pathway by interacting with the multidomain members of the Bcl-2 family to induce mitochondrial outer membrane permeabilization (2,3). P53 stimulates Bax and inhibits Bcl-2 (anti-apoptotic protein from Bcl-2 family). Bax can dimerize with itself or Bcl-2, and when it is overproduced, Bax homodimers promote apoptosis. In contrast, when Bcl-2 is in excess, Bcl-2 homodimers predominate and cells are protected from death (26). Consequently, the ratio Bcl-2/Bax represents a cell death switch, which determines the viability of cells in response to an apoptotic stimulus; i.e. when Bcl-2/Bax ratio decreases, the cellular resistance to apoptotic stimuli also decreases, leading to increased cell death and reduced incidence of tumours (27). In our study we did not observe significant differences in the Bcl-2/Bax ratio between the lesions analyzed. Nevertheless, we identified that all morphological areas of UA presented a trend for Bcl-2/Bax ratio >1, which may indicate a similarity of the apoptosis dysregulation in UA. Moreover, Zhang *et al.* (28) describes that a Bcl-2/Bax ratio >1 prevents spontaneous apoptosis in oral squamous cell carcinoma, which leads to an accumulation of tumour cells. In this sense, the determination of the Bcl-2/Bax ratio could be indicated in the assessment of the dysregulation of apoptosis in odontogenic lesions.

Among the limitations should be considered that: Our evaluation was based on a descriptive study and does not allow a functional evaluation of these proteins, future investigations could complement our findings through other techniques, and the follow-up of patients and the

consolidation of other clinical information is limited by the diagnostic characteristics of our research centre.

## Conclusions

The effect of mutant p53 activity over Bcl-2 and Bax expression could be relevant for the development and growth of odontogenic tumours and cysts. There is a tendency for an increased expression of p53 and Bcl-2 in solid tumours (CA) and focal areas of mural ameloblastomatous proliferation for UA compared to lesions with a cystic morphology (OKC and LUA). Further investigation is required to elucidate the interactions between both proteins and their role in the pathogenesis of odontogenic lesions.

## References

1. Elmore S. Apoptosis: a review of programmed cell death. *Toxicologic Pathology*. 2007;35:495-516.
2. Vaseva A V, Moll UM. The mitochondrial p53 pathway. *Biochimica et Biophysica Acta (BBA) - Bioenergetics*. 2009;1787:414-20.
3. Hemann MT, Lowe SW. The p53-Bcl-2 connection. *Cell Death Differ*. 2006;13:1256-1259.
4. Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. *Discovery medicine*. 2010;9:145-52.
5. Chaudhary Z, Sangwan V, Pal US, Sharma P. Unicystic ameloblastoma: A diagnostic dilemma. *Case Reports Natl J Maxillofac Surg*. 2011;2:89-92.
6. Vered M, Wright JM. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Odontogenic and Maxillofacial Bone Tumours. *Head and neck pathology*. 2022;16:63-75.
7. Kalogirou EM, Thermos G, Zogopoulos V, Foutadakis S, Michalopoulos I, Agelopoulos M, et al. The immunohistochemical profile of basal cell nevus syndrome-associated and sporadic odontogenic keratocysts: a systematic review and meta-analysis. *Clinical oral investigations*. 2021;25:3351-67.
8. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. *British journal of cancer*. 2011;104:1440-51.
9. Bree AF, Shah MR. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). *American journal of medical genetics Part A*. 2011;155A:2091-7.
10. Clark P, Marker P, Bastian HL, Krogdahl A. Expression of p53, Ki-67, and EGFR in odontogenic keratocysts before and after decompression. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*. 2006;35:568-72.
11. Knudson CM, Johnson GM, Lin Y, Korsmeyer SJ. Bax accelerates tumorigenesis in p53-deficient mice. *Cancer research*. 2001;61:659-65.
12. Vousden KH, Lu X. Live or let die: the cell's response to p53. *Nature Reviews Cancer*. 2002;2:594-604.
13. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IM, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. *Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc*. 2011;24:1248-53.
14. García-Iglesias MJ, Cuevas-Higuera JL, Bastida-Sáenz A, de Garnica-García MG, Polledo L, Perero P, et al. Immunohistochemical detection of p53 and pp53 Ser(392) in canine hemangiomas and hemangiosarcomas located in the skin. *BMC veterinary research*. 2020;16:239.
15. Singh A, Jain A, Shetty DC, Rathore AS, Juneja S. Immunohistochemical expression of p53 and murine double minute 2 protein in

- odontogenic keratocyst versus variants of ameloblastoma. *Journal of cancer research and therapeutics*. 2020;16:521-9.
16. Sharifi-Sistani N, Zartab H, Babakoochi S, Saghravanian N, Jamshidi S, Esmaili H, et al. Immunohistochemical comparison of the expression of p53 and MDM2 proteins in ameloblastomas and keratocystic odontogenic tumors. *The Journal of craniofacial surgery*. 2011;22:1652-6.
  17. Tenório JR, Santana T, Queiroz SIML, de Oliveira DHIP, Queiroz LMG. Apoptosis and cell cycle aberrations in epithelial odontogenic lesions: An evidence by the expression of p53, Bcl-2 and Bax. *Medicina oral, patologia oral y cirugía bucal*. 2018;23:e120-5.
  18. Shetty DC, Urs AB, Godhi S, Gupta S. Classifying odontogenic keratocysts as benign cystic neoplasms: a molecular insight into its aggressiveness. *Journal of Maxillofacial and Oral Surgery*. 2010;9:30-4.
  19. Singh T, Chandu A, Clement J, Angel C. Immunohistochemistry of Five Molecular Markers for Typing and Management of Ameloblastomas: A Retrospective Analysis of 40 Cases. *Journal of maxillofacial and oral surgery*. 2017;16:65-70.
  20. Lo Muzio L, Staibano S, Pannone G, Buccì P, Nocini PF, Buccì E, et al. Expression of cell cycle and apoptosis-related proteins in sporadic odontogenic keratocysts and odontogenic keratocysts associated with the nevoid basal cell carcinoma syndrome. *Journal of dental research*. 1999;78:1345-53.
  21. Doll C, Dauter K, Jöhrens K, Hartwig S, Voss JO, Klein M, et al. Clinical characteristics and immunohistochemical analysis of p53, Ki-67 and cyclin D1 in 80 odontogenic keratocysts. *Journal of stomatology, oral and maxillofacial surgery*. 2018;119:359-64.
  22. Slusarenko da Silva Y, Stoelinga PJW, Grillo R, da Graça Naclério-Homem M. Cyst or Tumor? A systematic review and meta-analysis on the expression of p53 marker in Odontogenic Keratocysts. *Journal of cranio-maxillo-facial surgery: official publication of the European Association for Cranio-Maxillo-Facial Surgery*. 2021;49:1101-6.
  23. Soluk Tekkeşin M, Mutlu S, Olguç V. Expressions of bax, bcl-2 and Ki-67 in odontogenic keratocysts (Keratocystic odontogenic tumor) in comparison with ameloblastomas and radicular cysts. *Türk Patoloji Dergisi/Turkish Journal of Pathology*. 2012;28:49-55.
  24. González-González R, Molina-Frechero N, Damian-Matsumura P, Salazar-Rodríguez S, Bologna-Molina R. Immunohistochemical expression of Survivin and its relationship with cell apoptosis and proliferation in ameloblastomas. *Disease markers*. 2015;2015:301781.
  25. Rangiani A, Motahary P. Evaluation of bax and bcl-2 expression in odontogenic keratocysts and orthokeratinized odontogenic cysts: A comparison of two cysts. *Oral Oncology*. 2009;45:e41-4.
  26. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. *Cell*. 1993;74:609-19.
  27. Vaskivuo TE, Stenbäck F, Tapanainen JS. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma. *Cancer*. 2002;95:1463-71.
  28. Zhang M, Zhang P, Zhang C, Sun J, Wang L, Li J, et al. Prognostic significance of Bcl-2 and Bax protein expression in the patients with oral squamous cell carcinoma. *Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*. 2009;38:307-13.

#### Acknowledgements

The authors would like to thank the Faculty of Dentistry, University of Chile, Santiago, Chile, for financially supporting this project (supported by FIOUCH 13-003) and the Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain (PhD Program in Medicine and Translational Research). FGV acknowledges partial support from CONICYT-PFCHA/Doctorado Nacional 2019-Folio 21190421. Thanks to Mr. Juan Fernández de los Ríos, from the Language and Translation services, Faculty of Dentistry, Universidad de Chile, for kindly proofreading and checking the spelling and grammar of this article.

#### Ethical aspects

This study was approved by the Ethics Committee (#2013/11) and the Institutional Biosecurity Committee (FDO#15) of the Faculty of Dentistry, University of Chile, Santiago, Chile.

Ethical responsibilities.

Protection of people and animals. The authors declare that no experiments have been carried out on humans or animals for this research. Confidentiality of data. The authors declare that they have followed the protocols of their research center on the publication of patient demographic data. Right to privacy and informed consent. The authors declare that no personal data of the patients appear in this article.

#### Source of funding

Project FIOUCH 13-003, Faculty of Dentistry, University of Chile, Grant/ Award Number: FIOUCH 13-003; CONICYT-PFCHA/Doctorado Nacional 2019, Grant/Award Number: Folio 21190421

#### Authors' contributions

Enrico Escobar: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Supervision; Writing-original draft; Writing-review & editing. Fernán Gómez-Valenzuela: Data curation; Formal analysis; Investigation; Supervision; Writing-original draft; Writing-review & editing. Cristian Peñafiel: Data curation; Methodology; Resources. Eduardo Chimenos-Küstner: Formal analysis; Supervision; Writing-review & editing. Ricardo Pérez-Tomás: Conceptualization; Formal analysis; Investigation; Supervision; Validation; Writing-review & editing.

#### Conflict of Interest

The authors declare that there is no conflict of interests regarding the publication of this paper.